ARA-290 in Small Fiber Neuropathy: What Clinical Trials Show

Key Takeaways

• Targeted mechanism: ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide derived from erythropoietin that selectively activates the innate repair receptor (IRR) without stimulating red blood cell production.
• Clinical focus: Human trials have primarily investigated ARA-290 in patients with sarcoidosis-associated small fiber neuropathy (SFN) and painful diabetic peripheral neuropathy.
• Structural regeneration signals: Phase 2 trials utilizing corneal confocal microscopy (CCM) observed increases in corneal nerve fiber abundance and length following 28-day administration protocols.
• Symptomatic endpoints: Initial pilot studies reported reductions in neuropathic pain and improvements on the Small Fiber Neuropathy Screening List (SFNSL), though later dose-ranging studies showed variable separation on patient-reported questionnaires.
• Regulatory status: ARA-290 is an investigational compound; it has received Orphan Drug and Fast Track designations for specific orphan indications but is not approved by the FDA or EMA for clinical use.

Understanding Small Fiber Neuropathy and ARA-290

Small fiber neuropathy (SFN) is a peripheral nerve disorder characterized by structural damage or selective loss of unmyelinated C-fibers and thinly myelinated Aδ-fibers. These small-caliber nerve fibers innervate the epidermis and mediate thermal sensation, mechanical nociception (pinprick perception), and autonomic functions. Damage to these pathways frequently produces debilitating burning pain, dysesthesias, allodynia, and autonomic disturbances.

While SFN frequently occurs secondary to metabolic conditions like diabetes mellitus or systemic inflammatory disorders such as sarcoidosis, conventional pharmacological management relies almost entirely on symptomatic analgesics. Anticonvulsants (such as gabapentin and pregabalin), tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors modulate central or peripheral pain processing but do not arrest underlying axonal degeneration or stimulate neuroregeneration. Consequently, researchers have focused on disease-modifying agents capable of suppressing neuroinflammation while promoting axonal repair. ARA-290 small fiber neuropathy research emerged to investigate whether selective receptor signaling could achieve structural nerve restoration in human subjects.

Mechanism: The Innate Repair Receptor (IRR) Pathway

ARA-290 (also known as cibinetide or helix-B surface peptide) is a synthetic 11-amino-acid peptide engineered from the spatial structure of the B-helix of human erythropoietin (EPO). Native erythropoietin exerts both hematopoietic effects (via a homodimeric erythropoietin receptor complex, EPOR2) and tissue-protective effects. However, using native EPO at high doses for neuroprotection carries severe risks of polycythemia, hypertension, and thromboembolism due to continuous EPOR2 activation.

ARA-290 was designed to selectively bind the innate repair receptor (IRR), a heteromeric complex composed of the erythropoietin receptor monomer (EPOR) and the common beta subunit (CD131 / βc). The IRR is minimally expressed in healthy tissues but is rapidly upregulated on inflammatory cells, endothelial cells, and injured neurons following tissue stress or inflammatory signaling. Binding of ARA-290 to the IRR triggers anti-inflammatory and cytoprotective cascades—principally via the inhibition of NF-κB activation and downstream pro-inflammatory cytokines—without binding the homodimeric EPOR2 receptor. As a result, ARA-290 promotes tissue repair and attenuates neuropathic hypersensitivity without altering red blood cell counts or hematocrit levels.

Clinical Trial Evidence in Sarcoidosis-Associated SFN

The primary clinical development program for ARA-290 focused on patients suffering from small fiber neuropathy associated with systemic sarcoidosis. Because sarcoidosis-induced neuropathy involves widespread immune dysregulation and chronic cytokine elevation, it provided a targeted human model to test IRR activation.

The Phase 2a Pilot Study

The initial clinical evaluation was a randomized, double-blind, placebo-controlled pilot study conducted by Heij and colleagues (PubMed: 23169252). The trial enrolled 22 patients with sarcoidosis and severe painful SFN (spontaneous pain score ≥5 on the Brief Pain Inventory). Participants were randomized to receive intravenous (IV) ARA-290 (2 mg) or placebo three times weekly for 4 weeks.

At 4 weeks, the ARA-290 group demonstrated a statistically significant reduction in neuropathy symptoms measured by the Small Fiber Neuropathy Screening List (SFNSL) compared to placebo (Δ -11.5 ± 3.04 vs. Δ -2.9 ± 3.34). Furthermore, significant improvements were observed in the bodily pain and physical functioning domains of the SF-36 health survey. Laboratory evaluations revealed no clinically significant changes in hematology or blood biochemistry, confirming the absence of erythropoietic activation.

Phase 2 Subcutaneous Evaluation

Because intravenous administration is impractical for chronic outpatient therapy, subsequent trials evaluated subcutaneous (SC) delivery. In an exploratory crossover and extension study published by Dahan and colleagues (PubMed: 24136731), pharmacokinetic analyses in healthy volunteers and sarcoidosis patients confirmed that daily SC administration of 4 mg ARA-290 provided biological exposure comparable to the effective IV regimen. Patients treated for 28 consecutive days demonstrated reductions in neuropathic symptom scores, alongside the first objective signals of structural nerve regrowth visualized via ophthalmic imaging.

The Phase 2b Dose-Ranging Study

To establish dose dependency and confirm structural nerve regeneration, Culver and collaborators conducted a randomized, double-blind, placebo-controlled Phase 2b trial (NCT02039687; IOVS 2017). The trial randomized 64 sarcoidosis patients with confirmed small nerve fiber loss across four treatment arms: placebo, 1 mg, 4 mg, or 8 mg of daily subcutaneous ARA-290 for 28 days.

The primary endpoint assessed changes in corneal nerve fiber abundance using corneal confocal microscopy. The study documented statistically significant, dose-dependent increases in corneal nerve fiber area (CNFA) and corneal nerve branch density, with the 4 mg and 8 mg daily cohorts demonstrating the most pronounced structural regrowth. Interestingly, this structural regeneration correlated positively with functional mobility assessed by the 6-Minute Walk Test (6MWT). However, between-group differences on secondary patient-reported pain outcome measures were less pronounced than in earlier pilot studies, highlighting the complex relationship between anatomical nerve fiber recovery and subjective pain reporting.

Findings in Diabetic Peripheral Neuropathy

Beyond sarcoidosis, ARA-290 has been evaluated in metabolic small fiber neuropathy. In a randomized Phase 2 trial in patients with type 2 diabetes mellitus and painful distal sensorimotor neuropathy (Brines et al., PubMed: 25555291), participants received daily subcutaneous injections of ARA-290 (4 mg) or placebo for 28 days.

Patients receiving ARA-290 exhibited improvements in neuropathic symptoms and sensory thresholds compared to baseline. In subgroup analyses of patients presenting with significant baseline small fiber depletion, ARA-290 treatment was accompanied by an increase in corneal nerve fiber density (CNFD). Additionally, investigators observed favorable exploratory shifts in glycemic control (HbA1c) and lipid profiles, suggesting potential systemic metabolic modulation mediated through IRR pathways in peripheral tissues.

Corneal Confocal Microscopy: Measuring Structural Nerve Regrowth

A major challenge in peripheral neuropathy research has been identifying sensitive, objective biomarkers to track axonal degeneration and repair. Traditional skin biopsies measuring intraepidermal nerve fiber density (IENFD) at the distal calf are invasive, require histopathological processing, and display slow rates of observable re-innervation.

The ARA-290 clinical program extensively utilized in vivo corneal confocal microscopy (CCM). The sub-basal nerve plexus of the human cornea contains the highest density of small unmyelinated and thinly myelinated sensory fibers in the body. Because the cornea is transparent, CCM provides a non-invasive, high-resolution optical biopsy capable of quantifying:

• Corneal Nerve Fiber Density (CNFD): The total number of main nerve fibers per square millimeter.
• Corneal Nerve Branch Density (CNBD): The number of primary branches emerging from main fiber trunks.
• Corneal Nerve Fiber Area (CNFA): The total two-dimensional surface area occupied by nerve fibers, accounting for both fiber count and individual axonal caliber.

Analyses published by Dahan et al. and Culver et al. demonstrated that corneal small fibers regenerate rapidly—within 28 days—in response to ARA-290 administration, establishing CCM as a responsive surrogate marker for investigating small fiber neuroregenerative pharmacotherapies.

Safety Profile and Tolerability in Clinical Studies

Across Phase 1 and Phase 2 clinical trials, ARA-290 demonstrated a generally favorable safety and tolerability profile at doses ranging from 1 mg to 8 mg daily:

• Hematologic parameters: Repeated administration across 4-week periods produced no changes in hemoglobin, hematocrit, reticulocyte count, or platelet levels, confirming lack of EPOR2 erythropoietic activation.
• Cardiovascular safety: No significant alterations in blood pressure, heart rate, or electrocardiographic parameters were observed.
• Reported adverse events: Adverse events were predominantly mild to moderate. The most commonly reported events included transient injection-site discomfort, mild headache, and gastrointestinal symptoms, which occurred at rates comparable to placebo arms.
• Immunogenicity: No anti-drug neutralizing antibodies or systemic hypersensitivity reactions were reported during the completed 28-day treatment protocols.

Research Limitations and Unresolved Questions

While Phase 2 trials yielded promising proof-of-concept data, significant limitations remain in the published evidence:

• Short trial duration: Published human trials evaluated ARA-290 for a maximum of 28 consecutive days. Whether structural nerve improvements persist after cessation of therapy, or whether long-term maintenance dosing is required, has not been established.
• Small sample sizes: The largest clinical study evaluated 64 participants. Adequately powered, large-scale Phase 3 multicenter trials are necessary to confirm clinical efficacy and regulatory endpoints.
• Discordance between endpoints: While objective nerve regeneration was clearly demonstrated via corneal confocal microscopy, clinical symptom scores (such as pain scales) showed variable correlation with structural regrowth across studies.
• Development halt: The original developer (Araim Pharmaceuticals) ceased active clinical development operations prior to completing Phase 3 registration studies, leaving the regulatory program inactive.

Regulatory Status

ARA-290 (cibinetide) is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other national medicines authority for any therapeutic indication. Although the compound was granted Orphan Drug Designation and Fast Track status by the FDA for sarcoidosis-associated small fiber neuropathy during earlier clinical phases, it remains strictly an investigational research agent.

Frequently Asked Questions

What is the difference between ARA-290 and erythropoietin?

Erythropoietin (EPO) is a large glycoprotein hormone that binds the classical homodimeric EPO receptor (EPOR2) to stimulate red blood cell production, while also interacting weakly with the innate repair receptor. ARA-290 is a short synthetic 11-amino-acid peptide derived solely from the B-helix of EPO. It binds exclusively to the innate repair receptor (EPOR/CD131 heterodimer) and does not stimulate erythropoiesis, avoiding the risks of elevated hematocrit or thrombosis.

How is nerve regeneration measured in ARA-290 clinical trials?

Clinical studies primarily utilize corneal confocal microscopy (CCM), a non-invasive optical imaging method that directly visualizes the small sensory nerve plexus within the cornea. Researchers measure changes in corneal nerve fiber density, branch density, and total fiber area before and after treatment.

Has ARA-290 demonstrated efficacy in diabetic neuropathy?

In a Phase 2 trial of patients with type 2 diabetes and peripheral neuropathy, daily subcutaneous administration of ARA-290 for 28 days improved sensory symptoms and increased corneal nerve fiber density in patients with baseline fiber loss. However, these findings represent preliminary Phase 2 proof-of-concept data rather than conclusive Phase 3 confirmation.

Is ARA-290 approved for medical use?

No. ARA-290 is an investigational drug that has not received regulatory approval from the FDA or EMA. It is not available as an approved prescription medication.

References

• Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18(11):1430-1436. PubMed
• Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013;19(1):334-345. PubMed
• van Velzen M, et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs. 2014;23(4):541-550. PubMed
• Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2014;20(1):658-666. PubMed
• Culver DA, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 2017;58(6):BIO52-BIO60. IOVS
• ClinicalTrials.gov. Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis. Identifier: NCT02039687.
• Brines M, et al. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. Sci Rep. 2018;8(1):4734. PubMed

Research Summary

ARA-290 (cibinetide) represents a novel pharmacological strategy targeting the innate repair receptor to reduce neuroinflammation and promote peripheral nerve regeneration without activating erythropoiesis. Completed Phase 2 clinical trials in sarcoidosis-associated small fiber neuropathy and diabetic peripheral neuropathy provide consistent proof-of-concept evidence that daily subcutaneous administration can induce rapid structural regrowth of small sensory nerve fibers, as measured by corneal confocal microscopy. Human trials have documented a reassuring short-term safety profile with no erythropoietic or cardiovascular complications. However, the human evidence base remains constrained to small cohorts evaluated over 28-day treatment courses. ARA-290 is an unapproved investigational agent, and larger Phase 3 trials will be required to determine whether its anatomical neuroregenerative effects translate into durable clinical efficacy.